Earendil Labs Advances AI-Designed IBD Antibody Into Phase IIa Ulcerative Colitis Trial

New updates have been reported about Earendil Labs.

Earendil Labs has initiated a Phase IIa clinical trial for HXN-1001, its half-life extended anti-TL1A antibody, with the first ulcerative colitis patient now dosed and the Phase I healthy volunteer study in Australia fully enrolled. The randomized, placebo-controlled Phase IIa study will assess safety, tolerability, pharmacokinetics, and early signals of efficacy, marking a key clinical inflection point for the company’s inflammatory bowel disease portfolio.

HXN-1001, designed using Earendil’s AI-driven biologics platform, targets IBD indications including ulcerative colitis and Crohn’s disease and has shown superior potency versus benchmark TL1A programs in preclinical models. The molecule combines extended in vivo half-life of roughly eight weeks at projected therapeutic doses with high-concentration subcutaneous formulation, aiming to deliver less frequent dosing and greater convenience, while Phase I data to date show good tolerability at single doses up to 1,200 mg and multiple doses of 450 mg with low immunogenicity. President and Co-CEO Zhenping Zhu, M.D., Ph.D., emphasized that the strong early safety and pharmacokinetic profile supports rapid advancement of the program, while CEO Jian Peng, Ph.D., framed HXN-1001 as a potential best-in-class biologic that exemplifies the firm’s AI-native R&D strategy across autoimmune disease and oncology. For executives and investors, this milestone moves Earendil closer to value-defining efficacy data, validates its AI-enabled antibody engine in a competitive TL1A space, and positions the company for potential strategic partnerships or expansion of global development efforts in IBD if Phase IIa results are positive.